CLINICAL_TRIALS ClinicalTrials.gov record update

A Prospective, Multicenter, Randomized, Open-Label Phase II Study of ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06970912
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:35.391031+00:00
Published At: 2026-01-21T00:00:00+00:00
Record Updated At: 2026-01-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hormone Receptor-Positive Breast Cancer", "High-risk Breast Cancer", "Early-Stage Breast Cancer", "HER2-negative Breast Cancer", "ctDNA Monitoring", "Breast Cancer Early Stage Breast Cancer (Stage 1-3)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-21"
protocolSection.identificationModule.nctId: "NCT06970912"
protocolSection.identificationModule.officialTitle: "A Prospective, Multicenter, Randomized, Open-Label Phase II Study of ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.